Jasper Therapeutics Stock Alpha and Beta Analysis
| JSPR Stock | USD 3.15 0.02 0.64% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Jasper Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Jasper Therapeutics over a specified time horizon. Remember, high Jasper Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Jasper Therapeutics' market risk premium analysis include:
Beta 3.77 | Alpha (0.75) | Risk 8.78 | Sharpe Ratio (0.03) | Expected Return (0.26) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Jasper Therapeutics Backtesting, Jasper Therapeutics Valuation, Jasper Therapeutics Correlation, Jasper Therapeutics Hype Analysis, Jasper Therapeutics Volatility, Jasper Therapeutics History and analyze Jasper Therapeutics Performance. Jasper Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Jasper Therapeutics market risk premium is the additional return an investor will receive from holding Jasper Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Jasper Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Jasper Therapeutics' performance over market.| α | -0.75 | β | 3.77 |
Jasper Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Jasper Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Jasper Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Jasper Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Jasper Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Jasper Therapeutics shares will generate the highest return on investment. By understating and applying Jasper Therapeutics stock market price indicators, traders can identify Jasper Therapeutics position entry and exit signals to maximize returns.
Jasper Therapeutics Return and Market Media
The median price of Jasper Therapeutics for the period between Tue, Apr 29, 2025 and Mon, Jul 28, 2025 is 5.02 with a coefficient of variation of 20.0. The daily time series for the period is distributed with a sample standard deviation of 0.97, arithmetic mean of 4.83, and mean deviation of 0.77. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Jasper Therapeutics Will Have To Spend Its Cash Wisely | 05/29/2025 |
2 | Acquisition by Tucker Edwin Jonathan of 90000 shares of Jasper Therapeutics at 6.0 subject to Rule 16b-3 | 06/04/2025 |
3 | Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic ... | 07/07/2025 |
4 | JMP Securities Cuts Jasper Therapeutics Price Target to 12.00 | 07/08/2025 |
5 | Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to ... | 07/09/2025 |
6 | INVESTOR ALERT Pomerantz Law Firm Investigates ClaimsOn Behalf | 07/10/2025 |
7 | Evercore ISI Cuts Jasper Therapeutics Price Target to 20.00 | 07/11/2025 |
8 | INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR | 07/14/2025 |
9 | INVESTOR ALERT Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors of Jasper Therapeutics, Inc. - JSPR | 07/23/2025 |
About Jasper Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Jasper or other stocks. Alpha measures the amount that position in Jasper Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Current Ratio | 5.91 | 7.19 | 4.98 | 8.77 | Net Debt To EBITDA | 0.91 | 1.29 | 0.98 | 0.93 |
Jasper Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Jasper Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Jasper Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Jasper Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Jasper Therapeutics. Please utilize our Beneish M Score to check the likelihood of Jasper Therapeutics' management manipulating its earnings.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Jasper Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Jasper Stock Analysis
When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.